Tasigna cleared for use in children with rare leukemia
The US Food and Drug Administration is allowing use of Novartis’ Tasigna to treat paediatric patients with a rare form of leukaemia.
Read More
Tag: Tasigna
BMS, Novartis to test Mekinist/Opdivo combo
Novartis and Bristol-Myers Squibb have signed a clinical research pact to investigate the safety, tolerability, and efficacy of combining their respective drugs Mekinist and Opdivo.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
